ACTG has launched the HoT study (A5424), a pivotal phase 4 clinical trial aimed at evaluating the safety and efficacy of menopausal hormone therapy for women living with HIV. This randomized, double-blind, placebo-controlled trial will focus on women aged 40-60 who are experiencing moderate to severe vasomotor symptoms during the late menopausal transition or early post-menopause. Participants will receive either an estradiol gel with or without oral progesterone or a placebo over a 12-week period, following a preliminary observational phase to assess their symptoms.

The significance of this study lies in its potential to address the increased severity and frequency of vasomotor symptoms experienced by women living with HIV, which are associated with worsened mental health, cognitive function, and adherence to antiretroviral therapy (ART). Over 70% of women in the general population report these symptoms, but women with HIV face more severe challenges, leading to a detrimental impact on their quality of life and healthcare engagement. By specifically targeting this demographic, the HoT study aims to fill a critical gap in the literature and provide evidence-based guidance for clinicians managing menopausal symptoms in this population.

The implications of the HoT study extend beyond immediate symptom management; it has the potential to shift research paradigms regarding the intersection of HIV and menopausal health. By establishing a clearer understanding of how hormone therapy can alleviate vasomotor symptoms, this study could inform future therapeutic strategies and improve care protocols for aging women living with HIV. Furthermore, the focus on inclusivity, with a goal of enrolling at least 50% non-White or Latina participants, underscores the commitment to addressing health disparities within this vulnerable group.

Source: globenewswire.com